Skip to main content
FULC logo

FULC · Fulcrum Therapeutics, Inc.

$3.68 +0.06 (+1.66%) At close · Jul 21
Market Cap
$246.54M
Shares
66.63M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025
Executive Total
Alex C. Sapir $3,251,490
Alan Musso $1,807,125
Curtis Oltmans $1,482,850
Fiscal 2024
Executive Total
Patrick Horn $3,730,273
Curtis Oltmans $1,425,240
Alan Musso $1,251,760
Alex C. Sapir $1,003,300
Fiscal 2023
Executive Total
Alex C. Sapir $6,990,596
Curtis Oltmans $2,319,661
Mel Hayes $2,192,854
Alan Musso $1,879,833
Bryan Stuart $1,869,696
Robert J. Gould $424,501
Fiscal 2022
Executive Total
Bryan Stuart $3,971,756
Esther Rajavelu $3,349,680
Santiago Arroyo $1,875,318
Robert J. Gould $118,342
Fiscal 2021
Executive Total
Bryan Stuart $5,055,104
Fiscal 2020
Executive Total
Robert J. Gould $3,016,350
Bryan Stuart $1,774,715
Curtis Oltmans $1,357,367
Fiscal 2019
Executive Total
Robert J. Gould $3,889,353
Owen Wallace $1,559,523
Bryan Stuart $1,234,960
Fiscal 2018
Executive Total
Robert J. Gould $853,634
Key facts CIK 1680581 CUSIP 359616109 13F (30d) 16 filings 16 filers Visit website Investor relations